Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 201-208

  Chien, Chun Ru ^a,b   Shih, Ya Chen Tina ^c  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer care; Cost effectiveness; Health economic evaluation

Indexed keywords

BCG VACCINE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; GEMCITABINE; PACLITAXEL; PEMETREXED; PLATINUM;

CANCER SURVIVAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 84930484412     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S27770     Document Type: Review

References (24)

1. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933-980.
2. Chouaid C, Atsou K, Hejblum G, Vergnenegre A. Economics of treatments for non-small cell lung cancer. Pharmacoeconomics. 2009;27(2):113-125.
3. Vergnenègre A, Ray JA, Chouaid C, et al. Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. Clinicoecon Outcomes Res. 2012;4:31-37.
4. Bongers ML, Coupé VM, Jansma EP, Smit EF, Uyl-de Groot CA. Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. Pharmacoeconomics. 2012;30(1):17-34.
5. Herbst RS, Bajorin DF, Bleiberg H, et al. Clinical cancer advances 2005: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol. 2006;24(1):190-205.
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-2550.
7. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Silver Spring: US Food and Drug Administration; Bevacizumab [revised May 2012; cited: May 12, 2012]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125085s0238lbl.pdf. Accessed May 27, 2012.
8. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med. 2004;351(4):317-319.
9. Shih YC, Elting LS, Pavluck AL, Stewart A, Halpern MT. Immunotherapy in the initial treatment of newly diagnosed cancer patients: utilization trend and cost projections for non-Hodgkin's lymphoma, metastatic breast cancer, and metastatic colorectal cancer. Cancer Invest. 2010;28(1):46-53.
10. Bureau of Labor Statistics. Washington: US Bureau of Labor Statistics; Consumer Price Index (All Urban Consumers, item: medical care) [cited May 18, 2012]. Available from: http://data.bls.gov/timeseries/CUUR0000SAM. Accessed May 27, 2012.
11. International Monetary Fund. World Economic Outlook Database [cited May 18, 2012]. Available from: http://www.imf.org/external/pubs/ft/weo/2009/02/weodata/index.aspx. Accessed May 27, 2012.
12. Isla D, González-Rojas N, Nieves D, Brosa M, Finnern HW. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clin Transl Oncol. 2011;13(7):460-471.
13. Bischoff HG, Heigener DF, Walzer S, Nuijten M. Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. Lung Cancer. 2010;69 Suppl 1:S18-S23.
14. Stanisic S, Bischoff HG, Heigener DF, et al. Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC). Lung Cancer. 2010;69 Suppl 1:S24-S30.
15. Klein R, Muehlenbein C, Liepa AM, Babineaux S, Wielage R, Schwartzberg L. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2009;4(11):1404-1414.
16. Giuliani G, Grossi F, de Marinis F, Walzer S. Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy. Lung Cancer. 2010;69 Suppl 1:S11-S17.
17. Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer. Value Health. 2011;14(6):836-845.
18. Ahn MJ, Tsai CM, Hsia TC, et al. Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan. Asia Pac J Clin Oncol. 2011;7 Suppl 2:S22-S33.
19. Klein R, Wielage R, Muehlenbein C, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2010;5(8):1263-1272.
20. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227-1234.
21. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21(9):1804-1809.
22. http://www.nccn.org/index.asp. Fort Washington: National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Non-small cell lung cancer v2.2012 [cited December 17, 2011]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (free registration required). Accessed December 17, 2011.
23. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6(1):9-17.
24. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. New York: Oxford University Press; 2005.